From the Bari bombing tragedy to the first published clinical trial, a new method for targeting tumors with systemic drugs

The history of chemotherapy It is an emblematic case of innovation through the reconversion of knowledge. It all starts with the Port of Bari il December 2, 1943, when a German air attack hit Allied ships also loaded with mustard gas, a chemical agent already known for use in World War IIn the following days, military doctors observed an anomalous clinical picture in the survivors: severe hemorrhages, recurrent infections and a collapse of white blood cells and platelets. The autopsy and blood tests showed direct damage to the bone marrow, with blockage of blood cell production.

That effect, devastating in a wartime context, suggested an opposite hypothesis in oncology: if a substance were capable of halting cell proliferation, it might also be able to target tumor cells characterized by rapid and uncontrolled growth. It was a radical shift in perspective, transforming a chemical weapon into a potential therapeutic tool. That insight already contained one of the founding principles of modern pharmacological oncology: the possibility of using systemic compounds not to act on a specific organ, but to target malignant cells widespread throughout the body or invisible to surgery.

The transition from military secrecy to clinical medicine

After the war, the data collected in the military were transferred to American university centers. The symbolic moment of this transition is the April 5, 1946, when the first clinical results on the therapeutic use of the nitrogen mustards therapy in patients with LymphomaThe lead authors of the study were Louis Sanford Goodman e Alfred Gilman, pharmacologists of theYale University, together with the surgeon Gustaf Lindskog, who had directly followed the treated patients.

When the prestigious scientific journal “Science” came out with an article entitled “The Biological Actions and Therapeutic Applications of the B-Chloroethyl Amines and Sulfides”, it was the first time the scientific world learned that mustard gas derivatives could reduce tumors. That shift wasn't just editorial, but cultural: knowledge that had remained confined to the realm of war and shrouded in secrecy was reformulated as medical knowledge that could be shared, debated, and replicated.

The protocol was rudimentary by today's standards: a mustard gas derivative was administered intravenously at empirically calculated doses. The results showed a rapid reduction in tumor mass and compressive symptoms, but also an equally rapid recurrence after treatment was stopped. There was no talk of a cure, but for the first time, it demonstrated that a systemic drug could induce measurable tumor regression. It was a turning point because it challenged the then-prevalent idea that cancer could be fought only with local means, such as scalpels and radiation, and paved the way for a medicine capable of acting on the entire body.

The first protocols and the birth of innovative therapeutic cycles

The temporary nature of the clinical response led to a first organizational innovation: the scheduled repetition of administrations. Thus the concept of cycles of chemotherapy, with intervals designed to allow for recovery of the bone marrow between one dose and the next. This principle, already defined at the end of the 1940s, remains the basis of most oncology protocols today. The logic was simple but crucial: target the tumor at its most vulnerable point and give healthy tissue the time it needs to regenerate.

At the same time, new mechanisms of action were tested. At the end of the decade, folic acid antagonists came into use, including methotrexate. In 1948, a child with acute lymphoblastic leukemia achieved a complete, albeit temporary, remission. In the Fifties, the same drug also showed efficacy in solid tumors such as breast cancer and in placental choriocarcinoma, significantly expanding the scope of chemotherapy.

During this phase, a new way of looking at cancer also took shape: no longer just an anatomical mass to be removed, but a cellular and biochemical disease whose internal mechanisms needed to be understood. Oncological pharmacology thus emerged as a frontier discipline, suspended between clinical practice, physiology, pathology, and organic chemistry.

From DNA to drugs that block cell division

The discovery of the structure of the DNA: He directed research toward molecules capable of interfering with genetic duplication and mitosis. Three large families developed: intercalating substances, which inserted themselves between the bases of DNA; drugs that blocked cellular metabolism, such as antifolates; and the poisons of the mitotic spindle, including the vinca alkaloids, which prevented chromosomes from separating during cell division. These classes were gradually joined by increasingly refined alkylating agents, antitumor antibiotics, and molecules capable of selectively destabilizing tumor proliferation.

From a biological point of view, these drugs acted on rapidly proliferating cells, but without distinguishing between tumor cells and healthy cells. This is where the most well-known side effects came from (myelosuppression, mucositis, alopecia) that made the treatment effective, but difficult to sustain. Furthermore, it became clear that apparently similar tumors responded very differently, introducing the issue of biological heterogeneity and treatment resistance. For this reason, chemotherapy also contributed to changing the clinical lexicon of oncology: alongside histological diagnosis, concepts such as response, remission, progression, dose-limiting toxicity, and clinical benefit came into play.

Polychemotherapy and new generation of drugs

In Sixties, the response to drug resistance was the combination of multiple molecules with different mechanisms. polychemotherapies They became particularly popular in leukemias and lymphomas, with protocols aimed at simultaneously targeting multiple phases of the cell cycle. The underlying idea was that a tumor could be subjected to multiple pressures, reducing the likelihood that a single cell population would rapidly develop resistance.

The leap in quality came in the Seventies with the introduction of more potent and better characterized drugs. Among these, a central role was played by anthracyclines, also developed thanks to Italian research, which became one of the cornerstones of the therapy of numerous solid and hematological tumors. Following, the platinum salts and taxanes radically changed the prognosis of cancers such as ovarian, lung, and testicular cancer. In testicular cancer in particular, the combination of surgery, monitoring, and drugs such as cisplatin transformed, within a few years, an often lethal neoplasm into one of the most emblematic cases of highly curable oncology.

According to the European oncology registries updated between 2022 and 2024, five-year survival for many solid tumors has exceeded the sixty percent, with improvements largely attributable to the combined use of surgery, radiotherapy, and chemotherapy. This data does not mean that chemotherapy alone explains all the progress, but it confirms its role as a therapeutic platform capable of integrating with different approaches, adapting over time to the evolution of oncology medicine.

Early chemotherapy: adjuvant as well as neoadjuvant

Another innovation concerns the timing of treatment. The therapy adjuvant, administered after surgery, aims to eliminate any residual tumor cells. Today it is standard in breast cancer and in colorectal cancer, with a reduction in the relative risk of recurrence and death between thirty and forty percentThe principle is to treat minimal residual disease before it becomes clinically visible again, when the tumor burden is lowest and the likelihood of systemic control is greatest.

The therapy neoadjuvant, administered before surgery, allows for a reduction in the volume of the tumor, making less invasive interventions possible. rectal cancer, the combination with preoperative radiotherapy has improved both local control and post-surgical quality of life, without worsening survival. In other contexts, such as breast or some gastroesophageal cancers, preoperative treatment also allows for in vivo assessment of the tumor's biological sensitivity to drugs, transforming therapeutic response into an additional source of clinical information.

“The innovation in chemotherapy has not only been molecular, but also strategic,”

explains Carmine Pinto, director of Oncology at theLocal Health Authority-IRCCS of Reggio Emilia.

“Integration with surgery, radiotherapy, and now immunotherapy allows us to develop increasingly personalized treatments, reducing unnecessary treatments and increasing overall efficacy.”

Chemotherapy in the era of precision medicine

In the current panorama, chemotherapy coexists with immunotherapy, targeted therapies e hormone therapy, which remains central in hormone-sensitive tumors. However, in addition to the fifty percent In oncology care, at least one chemotherapy phase remains indicated, often as the basis for more complex combinations. It is therefore not a relic of the past, but a clinical technology that continues to play a fundamental role in daily practice.

Innovation today also concerns patient selection, the use of predictive biomarkers and dosage optimization. In Switzerland, where a significant portion of European oncology clinical trials are concentrated, work is increasingly focused on dynamically adapting treatment regimens. The issue is no longer simply choosing which drug to use, but rather defining for whom, in what sequence, in what combination, and with what intensity. In this context, the availability of genomic profiles, advanced imaging, and longitudinal data allows for limiting ineffective treatments and more precisely calibrating the balance between expected benefit and toxicity.

“Chemotherapy is now an integral part of precision medicine, supported by clinical, genomic and radiological data,”

observes Solange Peters, director of the Department of Oncology of the Vaud University Hospital Center of Lausanne.

“It is not a technology of the past, but a platform that continues to evolve.”

It should be added that a significant portion of recent innovation also concerns patient support: more effective antiemetic drugs, hematopoietic growth factors, clinical nutrition, home monitoring, and adverse effect management pathways have made treatments more tolerable than in the past. The history of chemotherapy, therefore, coincides not only with that of antitumor molecules, but also with the construction of a clinical ecosystem capable of supporting patients throughout their treatment journey.

A symbolic date in the history of healthcare innovation

From the night of December 1943 a Bari upon publication of theApril 1946 signed by Goodman, Gilman e Lindskog, the chemotherapy It arises from a combination of clinical observation, technology transfer, and pharmacological experimentation. It is an example of how medical innovation proceeds through accumulation, adaptation, and integration between different disciplines. Its evolution also demonstrates that healthcare progress does not always occur through sudden breakthroughs, but often through successive corrections, dose adjustments, new combinations, and a better understanding of biological mechanisms.

Today, while theoncology As the world moves toward increasingly personalized and data-driven treatments, that origin remains a timely lesson: even discoveries born in dramatic contexts can become, if correctly interpreted and developed, lasting foundations for medical progress and for the construction of new care models. In this sense, the April 5th, eighty years ago It does not only represent a date in medical history, but a symbolic passage in the history of innovation: the moment in which knowledge born of destruction was reoriented towards the concrete possibility of saving lives.

The Birth of Chemotherapy as Told by Yale University

Here are three insights that might interest you:

Metal oxide in tumors to enhance röntgen therapy
Thus a human brain affected by tumor was reproduced in 3D
From PSI an unprecedented effective combined treatment of cancer